EGFR and lung carcinoma: In acquired resistance to EGFR inhibitors, pAKTser473 level was elevated in lung cancer, and increased pAKTser473 level was suggested as a predictive biomarker for EGFR tyrosine-kinase inhibitors (TKIs) response29.